Sandrock D, Lastoria S, Magrath I T, Neumann R D
Department of Nuclear Medicine, National Cancer Institute, National Institutes of Health, Bethesda, MD.
Eur J Nucl Med. 1993 Feb;20(2):119-22. doi: 10.1007/BF00168871.
Two hundred and thirty-four scintigraphic studies were performed in 34 patients (27 men, 7 women, age 17.3 +/- 7.7 years) with small, non-cleaved cell lymphoma who had follow-up for 3-96 months (mean 21.6 +/- 21.7 months). Whole-body scintigraphy was performed 48-72 h following i.v. injection of 370 MBq gallium-67 citrate. "Gold standards" for truth determinations were surgery, autopsy, histology, axial x-ray computed tomography, magnetic resonance imaging, ultrasonography and clinical follow-up. Overall, 181 of 234 studies were true negative. Eighty proven sites of disease had true positive 67Ga uptake (in 21 patients/37 studies). Nineteen sites (in 12 patients/15 studies) were false positive. In addition, 31 benign lesions were detected and interpreted correctly in terms of non-malignancy. Ten lymphoma sites (in 6 patients/10 studies) were missed by scintigraphy. Overall, sensitivity of gallium scintigraphy was 89% when calculated by sites and 79% when calculated by studies. Corresponding specificities were 91% and 92%, respectively. Positive predictive values were 81% (sites) and 71% (studies), and negative predictive values 95% (sites and studies). Thus, gallium scintigraphy proved to be a sensitive and specific method for staging and follow-up in patients with small, non-cleaved cell lymphoma.
对34例（27例男性，7例女性，年龄17.3±7.7岁）小无裂细胞淋巴瘤患者进行了234次闪烁扫描研究，随访时间为3 - 96个月（平均21.6±21.7个月）。静脉注射370MBq柠檬酸镓后48 - 72小时进行全身闪烁扫描。用于确定真实情况的“金标准”包括手术、尸检、组织学、轴向计算机断层扫描、磁共振成像、超声检查和临床随访。总体而言，234次研究中有181次为真阴性。80个已证实的病灶部位镓-67摄取呈真阳性（21例患者/37次研究）。19个部位（12例患者/15次研究）为假阳性。此外，还正确检测并解读了31个良性病变，判断为非恶性。闪烁扫描遗漏了10个淋巴瘤部位（6例患者/10次研究）。总体而言，以病灶部位计算时，镓闪烁扫描的敏感性为89%，以研究次数计算时为79%。相应的特异性分别为91%和92%。阳性预测值为81%（病灶部位）和71%（研究次数），阴性预测值为95%（病灶部位和研究次数）。因此，镓闪烁扫描被证明是小无裂细胞淋巴瘤患者分期和随访的一种敏感且特异的方法。
